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Previous studies suggested that omega-3 fatty acids (FAs) have therapeutic effects against depression, but there is no evidence in the
oncological setting. Our preliminary study reported the association between lower omega-3 FA intake and occurrence of depression
in lung cancer patients. To explore the association further, the present study examined whether depression was associated with
lower levels of omega-3 FAs in serum phospholipids. A total of 717 subjects in the Lung Cancer Database Project were divided into
three groups by two cutoff points of the Hospital Anxiety and Depression Scale depression subscale (HADS-D). In all, 81 subjects of
the nondepression and minor depression groups (HADS-Do5 and 5pHADS-Dp10, respectively) were selected to match with 81
subjects of the major depression group (HADS-D410) for age, gender, clinical stage, and performance status. Fatty acids were
assayed by gas chromatography and compared among the three matched groups. There were no differences between the major
depression group and nondepression group in any FAs. The minor depression group had higher mean levels of docosahexaenoic acid
(mean7s.d. (%), nondepression: 7.4071.54; minor depression: 7.9071.40; major depression: 7.2571.52, P¼0.017). These results
suggested that serum FAs are associated with minor, but not major, depression in lung cancer patients.
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Major and minor depressions are one of the most common
psychiatric problems in clinical oncological settings (Derogatis
et al, 1983; Razavi and Stiefel, 1994; McDaniel et al, 1995).
Docosahexaenoic acid (DHA), one of the omega-3 fatty acids
(FAs), is a major component of membrane FAs in brain neural
cells and lack of DHA has been shown to alter neural transmission
in animal studies (Bruinsma and Taren, 2000; Innis, 2000; Ng and
Innis, 2003). Previous studies have shown associations between
DHA or its precursor, eicosapentaenoic acid (EPA, omega-3 FA),
and major depression in subjects without cancer (Edwards et al,
1998; Hibbeln, 1998; Peet et al, 1998; Maes et al, 1999). Other
studies have shown their possible therapeutic potential with few
adverse effects in clinical trials (Nemets et al, 2002; Peet and
Horrobin, 2002; Su et al, 2003). In the oncological setting, the use
of antidepressants has been limited due to their adverse effects
(Akizuki et al, 2002; Fisch, 2004). In our previous pilot study to
obtain information for planning interventional research, depres-
sion in cancer patients was not associated with either EPA or DHA
intakes, but was associated with lower intake of alpha-linolenic
acid (ALA: major omega-3 FAs in diet, precursor of EPA and DHA)
(Suzuki et al, 2004). To elucidate any such association in detail, the
present study was designed to examine our hypothesis that lower
levels of omega-3 FAs (EPA, DHA) in serum phospholipids are
associated with major and minor depression in lung cancer
patients.
MATERIALS AND METHODS
Study design and subjects
The present study was a three matched group case–control study,
based in part on the Lung Cancer Database Project, which was a
prospective cohort study for investigation of the pathogenesis of
and development of new therapy for lung cancer at the National
Cancer Center Hospital East and the National Cancer Center
Research Institute East, Japan (Suzuki et al, 2004). The project,
including the present study, was approved by the Institutional
Review Board and the Ethics Committee of the National Cancer
Center, Japan. All patients provided their written informed consent
prior to enrolment in this study. The inclusion criteria of the
present study, containing those of the Lung Cancer Database
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sProject, were as follows: (1) patients who had visited the National
Cancer Center Hospital East for their clinically diagnosed but
never treated primary lung cancer between July 1999 and
November 2001; (2) patients who had been informed of their lung
cancer diagnosis; (3) patients who were physically able to complete
questionnaires; and (4) patients who provided the blood samples.
The exclusion criteria of the study were: (1) patients who had
cognitive impairment, such as dementia and delirium; (2) patients
whose medical attendants decided that their participation in the
study had problems in clinical service; (3) patients whose clinical
diagnosis of lung cancer had changed after a pathological report;
(4) patients who had a performance status of more than 2 points
(Eastern Cooperative Oncology Group) assessed by oncologists (to
avoid affecting the results due to severe physical condition); (5)
patients who had any past or current psychiatric disorder, except
for depression, according to their medical chart; (6) patients who
were taking antidepressants, major tranquilisers, and drugs for
thyroid disease according to their medical chart (to exclude the
effect on results by way of modifying depression); (7) patients who
had brain neoplasms or brain metastasis diagnosed by head CT
scan or MRI tests; and (8) patients who had a cerebral infarction
or hemorrhage diagnosed from the examination of CT scan or
MRI, or by clinical symptoms. During the corresponding period,
1013 patients were admitted to the Thoracic Oncology ward,
National Cancer Center Hospital East, Japan. In all, 42 patients
were ineligible, because of their poor physical conditions. Also, 30
patients refused to participate in this study and 39 patients could
not be contacted (e.g., because of emergency admission and the
immediate start of treatment). Of the remaining 902 patients, 829
patients provided blood samples and self-reported questionnaires,
including the Hospital Anxiety and Depression Scale (Zigmond
and Snaith, 1983). Based on all the exclusion criteria, 717 patients
were eligible for enrolment in the present study.
Measurement of depression
The self-reported questionnaires including the HADS were
completed during the waiting period prior to admission, and were
collected after admission. We used the HADS, which consists of
seven-item anxiety and seven-item depression subscales, to assess
anxiety and depressive symptoms during the preceding week in
medically ill patients. The Japanese version of HADS was validated
as having a good correlation of scores between test and retest
(r¼0.82) with Japanese subjects at the National Cancer Center
Hospital East, Japan (Kugaya et al, 1998). In this study, depression
was evaluated using the Hospital Anxiety and Depression Scale
(HADS-D), with two cutoff points of 10 out of 11 and four out of
five. These cutoff points have been found to yield a good sensitivity
and specificity for the screening of depression (10 out of 11; 82.4
and 95.1%, major depression only, four out of five; 91.5 and 58.0%,
adjustment disorder and major depression, respectively) (Kugaya
et al, 1998). In the present study, subjects with higher scores on
the HADS-D (410) were assigned to the major depression group,
those with middle scores on the HADS-D (5–10) formed the minor
depression group, and those with lower scores on the HADS-D
(o5) were placed in the nondepression group. By this classifica-
tion, all eligible samples (n¼717) were divided into three groups:
the major depression group (n¼81), the minor depression group
(n¼319), and the nondepression group (n¼317).
To select cases and controls for comparisons among the three
groups, all subjects in the major depression group (n¼81), which
was the smallest group of the three, were selected as standards to
collect the same numbers of matched subjects in the minor
depression and nondepression groups matched by gender, age,
performance status (PS: 0 or 1), and the clinical stage assessed by
TNM classification (Ia-IIIa or IIIb-IV). These subjects were pair-
matched by gender and age (within 5 years). PS and clinical stage
were considered as confounders on cancer patients, and were
exactly matched among the three groups. As the major depression
group included relatively more subjects at an advanced clinical
stage, selected subjects in the other two groups (n¼162) matched
with those in the major depression group had a worse PS
(Po0.001) and felt breathlessness more frequently (P¼0.028) than
the unselected subjects in the minor and nondepression groups
(n¼474), but apart from that there were no significant differences
in any other factors including gender, age, and quantity of FA
intake assessed by the Food Frequency Questionnaire (FFQ)
(Tsubono et al, 1996) between the selected and the unselected
subjects (data not shown).
Measurement of FA composition of serum phospholipids
Following an overnight fast, blood samples for this study were
collected early in the morning, a few days after admission, from all
participating subjects by registered nurses, together with those
for clinical examinations. Serum FAs were reflected by dietary
FA intake in the past 3 weeks (Zock et al, 1997). After storing the
samples for about 2h at 41C, serum was separated by centrifuga-
tion (1870g, 10min), and stored at  801C till measurements (4–5
years). Although, the present study did not confirm the influence
of long storage up to 5 years, a previous study indicates good
reproducibility to assay FA composition in serum samples stored
up to 12 years at  801C (Zeleniuch-Jacquotte et al, 2000). The
FA composition of the total phospholipids fraction in serum was
determined by experts (ST and SF) using gas chromatography.
Briefly, FAs were extracted by the method of Bligh and Dyer
(1959); the total phospholipids fraction was separated by thin-layer
chromatography; after transmethylation with HCl-methanol, the
FA composition was analysed by gas chromatography (GC14A
Shimadzu Corporation, Kyoto) with a capillary column DB-225
(inside diameter 0.25mm, 30m in length, 0.25mm film thickness;
J&W Scientific, Folsom, CA, USA); column temperature was kept
at 1701C for the first 1min, raised to 2201C at the rate of
41Cmin
 1, and kept at this temperature for 22min; and the whole
system was controlled with gas chromatography software, CLASS-
GC10 ver. 1.3 (Shimadzu Corporation, Kyoto, Japan). The intra-
assay coefficients of variance for EPA and DHA were 5.1 and 3.4%,
respectively (n¼10).
Assessment of demographical and medical backgrounds
Information about clinical, demographic and social factors was
collected from the database and medical chart in the same way as
in our previous study (Suzuki et al, 2004). These data contained
the following: gender, age, clinical staging assessed by TNM
classification, performance status, educational level (longer than 9
years), smoking status (current smoker, ex-smoker, or non-
smoker), alcohol consumption estimated by FFQ, degree of breath-
lessness and pain (present or absence), and body mass index.
Statistical analysis
For assessment of background factors, differences of continuous or
categorical variables were analyzed by one-way analysis of variance
(ANOVA) or the w
2-test, respectively.
The FA compositions of serum phospholipids were analysed by
one-way ANOVA and analysis of covariance (ANCOVA). When
any significant differences existed among the three groups, the
Tukey HSD post-hoc analyses were performed. The background
variables that were different in three groups were examined for
any relationship with FA composition by the Student’s t-test (for
categorical variables) or the Spearman’s rank correlation coeffi-
cient (for continuous variables). Only factors that were related to
both background and FA compositions were set as covariates for
the ANCOVA. All tests were two-tailed, with a P-value of o0.05
as the statistically significant level. Statistical analyses were
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sperformed using the statistical software package SPSS for Windows
(Version 11.0J, SPSS Japan Institute Inc.). As no study exists on
serum FAs in cancer patients with depression, the sample size was
estimated by referring to previous studies of depressive noncancer
patients (Maes et al, 1999; Frasure-Smith et al, 2004). According to
the previous studies, the differences of the mean values of EPA and
DHA between subjects with depression and normal controls were
22 and 14%, respectively. These differences were equivalent to the
effect size of 0.45 by using the data of means and standard errors
on FA compositions in Japanese healthy males (Kobayashi et al,
2001). The final size of samples needed for this study was
calculated at 77 in each group with setting of the effect size at 0.45,
with a two-tailed level of a at 0.05, and value of b at 0.20.
RESULTS
Backgrounds of matched subjects
Table 1 shows the background variables, gender, age, clinical stage,
and performance status, which were used for matching, and also
contains the educational level, smoking status, alcohol consump-
tion, and body mass index. None of them showed significant
differences among the three groups. Pathology of lung cancer
(w
2¼7.32, P¼0.50), presence of breathlessness (w
2¼5.87,
P¼0.058), and presence of pain (w
2¼0.20, P¼0.90) were also
concerned as variables; however, none of them showed significant
difference. The mean, median, standardised deviation, and range
of duration between the time points of performing the HADS and
blood sampling of all subjects were 3.6, 2.0, 5.0, and 0–33 days,
respectively. The durations were not significantly different among
the three groups (F¼0.54, P¼0.58).
Fatty acid compositions among the three groups
Table 2 shows the results of the ANOVA and the mean values for
the compositions of each of the omega-3 FAs in the three groups.
Significant differences were shown for DHA (F¼4.15, P¼0.017),
but no difference was seen in EPA levels (F¼1.16, P¼0.31) among
the three groups. Post-hoc analyses, contrary to our hypothesis,
failed to show any statistically significant difference between the
major and nondepression groups, but the minor depression group
had significantly higher levels of DHA composition (mean, s.d.
7.90%, 1.40) than the major depression group (7.25%, 1.52,
P¼0.017). The levels of DHA in the minor depression group were
higher than those in the nondepression group, although the P-
value did not show a statistical significance (7.40%, 1.54, P¼0.09).
There were also significant differences in docosapentaenoic acid
(22:5n-3) (F¼5.29, P¼0.006) and total omega-3 FAs (F¼3.91,
P¼0.021). There were no significant differences in ALA (data not
shown) and ratios of total omega-6 FAs to total omega-3 FAs (data
not shown).
As no variables could be identified with significant difference in
the three groups, no factor was detected as a covariate. In addition
to the main analyses, stratified analyses by gender were also
performed, but these results were not so different from those of the
main analyses (data not shown).
DISCUSSION
As far as we know, this is the first study investigating
an association between the levels of FAs in serum phospholipids
and depression in patients after diagnosis of their lung
cancer.
Table 1 Background of matching subjects(n¼243)
Nondepression Minor depression Major depression v
2 or FP -value
HADS-D (score) 0–4 5–10 11–21
Number 81 81 81
Gender (male) 57 (70%) 57 (70%) 57 (70%) 0.00 1.00
Age (years old) 65.078.3 65.478.4 65.178.3 0.05* 0.96
Performance status (0/1)
a 23/58 23/58 23/58 0.00 1.00
Clinical stage (IIIb–IV)
b 47 (58%) 47 (58%) 47 (58%) 0.00 1.00
Educational level (49 years) 56 (69%) 50 (62%) 52 (64%) 1.24 0.54
Alcohol (445gday
 1) 12 (15%) 12 (15%) 14 (17%) 0.51 0.77
Smoking
Current smoker 30 (37%) 27 (33%) 33 (41%) 1.32 0.86
Ex-smoker 31 (38%) 34 (42%) 32 (40%)
Nonsmoker 20 (25%) 20 (25%) 16 (20%)
Body mass index (kgm
 2) 22.173.2 22.172.9 22.073.5 0.04* 0.96
Age and body mass index: mean7s.d. PS: number. Others: number and percentage. *F-value.
aDefined by Eastern Cooperative Oncology Groups.
bDefined by TNM
Classification, International Union Against Cancer.
Table 2 Percentage of omega-3 fatty acids in serum phospholipids in three groups
Depression Compared groups
Non (n¼81) Minor (n¼81) Major (n¼81) Non vs Minor Non vs Major Minor vs Major





20:5n-3 (EPA) 2.9671.53 3.2471.45 2.9271.33 1.16 0.31 — — —
22:5n-3 1.0070.31 1.1170.36 0.9570.29 5.29 0.006 0.08 0.53 0.005
22:6n-3 (DHA) 7.4071.54 7.9071.40 7.2571.52 4.15 0.017 0.09 0.79 0.017
Total omega-3 11.7372.84 12.6372.70 11.5072.62 3.91 0.021 0.09 0.85 0.023
aPost-hoc analysis (Tukey HSD) was carried out only for fatty acids with significant difference. EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
Serum fatty acid and depression in cancer patients
M Kobayakawa et al
1331















sThere was no significant difference in the levels of EPA and
DHA in serum phospholipids between the major and nondepres-
sion groups, whereas the level of DHA was significantly higher in
the minor depression group. Our hypothesis that these FAs would
be lower in subjects with major and minor depression was
therefore not supported.
In our previous cross-sectional study to investigate the relation
between depression and omega-3 FA intake in patients with lung
cancer, no significant differences in EPA or DHA intake were
observed between subjects with depression (HADS-DX5) and
subjects without depression (HADS-Dp4). However, subjects with
depression had significantly lower intake of ALA, which was a
major dietary omega-3 FA (Suzuki et al, 2004). As ingested ALA
can be converted into EPA and DHA in vivo, the result of our
previous study (Suzuki et al, 2004) did not seem to be inconsistent
with the studies indicating lower levels of EPA and DHA in
phospholipids in depression (Edwards et al, 1998; Peet et al, 1998;
Maes et al, 1999). Then, in the present study, we hypothesised
that lower levels of EPA and DHA in serum phospholipids were
associated with major depression and minor depression in lung
cancer patients. However, the result of the present study did not
support the hypothesis. This might have been caused by the
relatively small rate of converting ALA to EPA and DHA, which
was suggested in a previous study in healthy adults (Pawlosky et al,
2001). The converting rate might be so small that the reduction of
ALA intake did not influence the reduction of the levels of EPA and
DHA in serum phospholipids.
Previous studies reported that levels of EPA and DHA in serum
or in the red blood cell membrane were lower in subjects with
major depression than in healthy controls (Edwards et al, 1998;
Peet et al, 1998; Maes et al, 1999). In the present study, there
were no differences in the levels of DHA and EPA in serum
phospholipids between subjects with major depression and
subjects without depression. There are several possible explana-
tions for the discrepancy in our findings. First, characteristics of
depression may explain the difference in results of the present
study from those of the previous studies. In the present study, all
subjects had a clear stressful event, which was cancer diagnosis.
Major depression in patients with cancer appears to be a reactive
depression induced by the stressful events caused by and related
to cancer (e.g., diagnosis, examination, therapy, and so on)
(Chochinov, 2001; Moorey and Greer, 2002). To date, one study
has reported no difference in the level of DHA in plasma
phospholipids between reactive depression diagnosed by clinical
interview and healthy controls (Fehily et al, 1981). Therefore, there
is a possibility that the lack of any association between major
depression and FAs in serum phospholipids in the present study
was related to the unique characteristic of depression in cancer
patients, such as the existence of clear stress and the patient’s
reaction to it. However, further research is needed before any
definitive conclusion can be reached.
Second, the different proportions of males and females in
subjects may be related to the different results. In the previous
studies, the ratio of males to females was 1:1 or smaller. In the
present study, about 70% of the subjects were males. A recent
population-based cross-sectional study nested to the ATBC study
showed no association between the intake of omega-3 FAs and
depression in Finnish males (Hakkarainen et al, 2004). Besides, the
other Finnish study reported a significant association between the
frequency of fish intake and depression in females, but not in males
(Tanskanen et al, 2001). These studies suggested the possibility that
there may be no relation between omega-3 FAs and depression in
males, which is consistent with our results. As subanalyses, the
stratified analyses by gender showed no significant associations
between FAs and depression in both genders. However, as the
statistical power of the subanalysis was diminished due to reduced
sample size particularly in females, further research is needed
before a solid conclusion can be reached.
Third, the difference in dietary habits may contribute to the
difference in results of the present study from those of the previous
studies. In the present study, all subjects were Japanese, whose
dietary habits are different from those in Western subjects,
particularly in the elderly (Sugano and Hirahara, 2000), and who
are reported to have relatively high intakes and high serum levels
of omega-3 FAs (more than three times those of Caucasian
Americans) (Iso et al, 1989). Hibbeln reported a higher consump-
tion of seafood and a lower prevalence of major depression in
Japan than in Western countries (Hibbeln, 1998). The small
amount of EPA and DHA, which was hypothesised as one of the
mechanisms of causing major depression in previous reports,
may have had little contribution towards developing major
depression in Japanese populations, who consume large quantities
of seafood.
Contrary to our hypothesis, the level of DHA in serum
phospholipids was significantly higher in subjects with minor
depression. Few studies have investigated the association between
minor depression and FAs. Maes et al (1996) performed a study to
compare FAs of serum phospholipids among three groups: a group
of 36 subjects with major depression, a group of 24 healthy
controls, and a group of 14 subjects with minor depression
including adjustment disorder with depressive mood and dys-
thymic disorder. Although the numbers of subjects with minor
depression in the study might be too small to show any significant
difference, the mean level of DHA in subjects with minor
depression seemed to be about 10% above of that of subjects with
major depression and healthy controls. The levels of DHA in
serum phospholipids in minor depression may be higher than
those in major depression and healthy controls. These findings
suggested that minor depression, including adjustment disorder,
dysthymic disorder, and the other subclinical form of depression,
might have a biological pathology on FAs different from that of
major depression.
The present study had the following limitations: (1) Subjects
with severe depression might be excluded in this study, because
subjects with poor physical activity, with cognitive impairment,
with worse performance status (X2), and on current antidepres-
sant medication were ineligible in this study. The inclusion of these
subjects might have affected the result. (2) Owing to the lack of any
data of FA compositions in the healthy controls, the influences
of lung cancer on serum FAs were unclear. (3) Depression was
defined by cutoff scores of the HADS-D, not by a structured
psychiatric interview (such as the Structured Clinical Interview for
DSM-IV, a widely recognised standard). The one point assessment
of HADS-D on its own might not be enough to measure depression
in the present study. (4) A previous study reported that serum FAs
were reflected by dietary FA intake in the past 3 weeks (Zock et al,
1997). In the present study, the durations of all subjects between
the time points of performing the HADS and blood sampling had
a mean value of 3.6 days and standardised deviation of 5.0 days,
and those of 95% of all subjects were under 15 days. In addition,
the durations of all subjects were not different among the three
compared groups. However, the influence of the durations cannot
be totally excluded. (5) Although the subjects in the present study
were matched by gender, age, clinical staging, and performance
status, the present study was unable to exclude all of the
confounding factors such as medications, smoking, alcohol
consumption, and common physical complications.
In conclusion, the levels of DHA and EPA in serum
phospholipids were not low in subjects with major and minor
depressions in Japanese lung cancer patients. This result was not
enough to encourage us to plan any further studies on interven-
tional research with these FAs for depression in lung cancer
patients. However, minor depression may be related to a high level
of DHA in serum phospholipids. A further study with healthy
controls and designed to exclude confounding factors is needed
before any definitive conclusion can be reached.
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